A detailed history of Royal Bank Of Canada transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 66,556 shares of BCRX stock, worth $483,862. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,556
Previous 76,822 13.36%
Holding current value
$483,862
Previous $474,000 6.54%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $65,805 - $89,211
-10,266 Reduced 13.36%
66,556 $505,000
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $179,407 - $294,957
-43,440 Reduced 36.12%
76,822 $474,000
Q1 2024

Nov 05, 2024

BUY
$4.89 - $7.65 $212,421 - $332,316
43,440 Added 56.55%
120,262 $610,000
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $32,953 - $51,553
6,739 Added 5.94%
120,262 $610,000
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $278,292 - $378,321
55,882 Added 96.95%
113,523 $680,000
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $89,893 - $106,104
13,397 Added 30.28%
57,641 $408,000
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $194,184 - $245,799
-27,900 Reduced 38.67%
44,244 $311,000
Q1 2023

May 15, 2023

SELL
$7.94 - $11.84 $100,758 - $150,249
-12,690 Reduced 14.96%
72,144 $601,000
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $610,312 - $825,375
58,125 Added 217.62%
84,834 $973,000
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $591,755 - $812,224
-54,843 Reduced 67.25%
26,709 $337,000
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $236,486 - $535,917
29,973 Added 58.11%
81,552 $863,000
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $316,455 - $540,930
-27,375 Reduced 34.67%
51,579 $839,000
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $238,379 - $329,638
21,322 Added 37.0%
78,954 $1.09 Million
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $313,145 - $388,953
22,037 Added 61.91%
57,632 $829,000
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $338,152 - $613,657
35,595 New
35,595 $563,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.35B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.